


EMERGING COMPANY PROFILE | REPRINT FROM OCT. 12, 2022

## Ascidian: correcting mutations via trans-splicing to edit RNA exons

BY PAUL BONANOS, ASSOCIATE EDITOR



BIOCENTURY & GETTY IMAGES

Launched by ATP with \$50 million, Ascidian believes its RNA trans-splicing technique will provide the capability to correct genetic mutations by mimicking a naturally occurring process, offering a safety advantage and greater therapeutic reach than other gene therapy and gene editing approaches.

Ascidian Therapeutics Inc. is developing RNA exon-editing molecules that can replace mutations with wild-type genetic material at the pre-mRNA stage. The approach is designed to produce durable results akin to most gene therapies, but the company believes it can address a wider variety of genes and mutations without using exogenous enzymes that can pose risks.

President and CEO Romesh Subramanian told BioCentury that the technique represents a differentiated category of therapeutics, providing a way to edit multiple exons at once without disrupting the genome, and without using foreign enzymes to avoid unwanted immunological effects that can occur with some gene editing approaches.

The molecules can also be delivered via viral or non-viral vehicles, including lipid nanoparticles, which may permit

Ascidian to correct large genes that couldn't be carried in smaller vectors.

The company's RNA exon editors are synthetic molecules that include a functional coding sequence meant to replace the patient's mutated exons, plus linking and binding domains. Upon delivery to pre-mRNA, the functional exons are swapped into the transcript and joined with the patient's normal exons in a process known as trans-splicing. Once introns are removed, the mature, corrected mRNA is translated into protein.

Until about two decades ago, trans-splicing had been observed only in small organisms. A 2001 paper in *Genes & Development* described the process as it occurred in a chordate, *Ciona intestinalis*, also known as a sea squirt or an ascidian.

Apple Tree Partners (ATP) CSO and venture partner Michael Ehlers told BioCentury that although researchers had sought for decades to use trans-splicing to edit genetic material for therapeutic benefit, the tools weren't available to do it successfully. He pointed to advances across several fields — high-throughput molecular biology, DNA barcoding, next-

generation sequencing, computational design and RNA biology — that have enabled Ascidian to attain better results.

He said the firm, the sole investor in Ascidian's series A round, was able to build much of the start-up's platform in-house, though it in-licensed some IP from the University of Pennsylvania.

Ascidian will first attempt to show clinical proof of concept via its lead program addressing the ABCA4 gene to treat retinopathies, including Stargardt disease. Ascidian has already presented non-human primate data showing that sub-retinal administration of the therapy led to full-length ABCA4 expression. It intends to complete IND-enabling work and begin a first-in-human trial. Subramanian declined to give a timeline, but said the start-up is working with regulators to start clinical work as soon as possible.

Ehlers said the ocular setting represented a "perfect use case" for Ascidian's technology, offering advantages via the eye's small and localized tissue. The ABCA4-related retinopathies are associated with a gene too large for standard adeno-associated viral vectors, with high mutational variance and an unmet need.

Subramanian said Ascidian's pipeline will also include programs for CNS and neuromuscular indications, and the platform's broad applicability will open the door to multiple indications.

Subramanian was most recently CEO and CSO at Dyne Therapeutics Inc., which he co-founded as an entrepreneur-in-residence at Atlas Venture. He has also been an employee at Alexion Pharmaceuticals Inc., Pfizer Inc. (NYSE:PFE) and RaNA Therapeutics Inc., which changed its name to Translate

---

## COMPANY PROFILE

### ASCIDIAN THERAPEUTICS INC.

Boston, Mass.

**Technology:** RNA exon editing

**Origin of technology:** In-house, University of Pennsylvania

**Disease focus:** Ophthalmology, neurology, musculoskeletal

**Clinical status:** Preclinical

**Founded:** 2020 by Apple Tree Partners

**Academic collaborators:** None

**Corporate partners:** None

**Number of employees:** 30

**Funds raised:** \$50 million

**Investors:** ATP

**CEO:** Romesh Subramanian

**Patents:** Undisclosed

---

Bio Inc. before Sanofi (Euronext:SAN; NASDAQ:SNY) acquired it in September 2021.

Ehlers was EVP of R&D at Biogen Inc. (NASDAQ:BIIB). He was Ascidian's founding CEO and became chairman upon Subramanian's arrival. He is also CEO of ATP portfolio company Intergalactic Therapeutics Inc., which is developing non-viral gene therapies that use covalently closed and circular DNA (C3DNA).

Although Subramanian declined to discuss Ascidian's current business development activities in detail, he said the company's financial strategy will include "a combination of equity and partnerships."

# BIOCENTURY

## BIOCENTURY INC.

---

BioCentury's mission is to provide value-added business intelligence & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

### NEWSROOM

news@biocentury.com

### SAN CARLOS, CA

+1 650-595-5333; Fax: +1 650-595-5589

### CHICAGO

+1 312-755-0798; Fax: +1 650-595-5589

### WASHINGTON, DC

+1 202-462-9582; Fax: +1 202-667-2922

### UNITED KINGDOM

+44 (0)1865-512184; Fax: +1 650-595-5589

BioCentury®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BIOCENTURY INC. All contents Copyright © 2022, BIOCENTURY INC. ALL RIGHTS RESERVED. No part of BioCentury's Publications or Website may be copied, reproduced, retransmitted, disseminated, sold, distributed, published, broadcast, circulated, commercially exploited in any form or used to create derivative works without the written consent of BioCentury. Information provided by BioCentury's Publications and Website is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of the information, nor does BioCentury make any warranties of any kind regarding the information. The contents of BioCentury's Publications and Website are not intended as investment, business, tax or legal advice, and BioCentury is not responsible for any investment, business, tax or legal opinions cited therein or for any decision made or action taken in reliance upon such information.

All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all

others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc.

**USE OF IMAGES:** Certain Images used in BioCentury Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "Legal" section on the footer of the homepage at [www.biocentury.com](http://www.biocentury.com).

**PRIVACY & ADVERTISING:** In accordance with its Privacy Policy, BioCentury does NOT sell its customer information or usage data to third parties. BioCentury sells advertising in its BioCentury product emails and on its website. BioCentury is pleased to acknowledge its conference and events partners and sponsors through promotional announcements, on our web site, at our events and in our product emails. BioCentury also provides advertising opportunities to partners, sponsors, and advertisers through stand-alone emails to our community.